Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Shares Outstanding (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Shares Outstanding for 6 consecutive years, with $52.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 0.59% to $52.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.6 million through Dec 2025, up 0.59% year-over-year, with the annual reading at $52.6 million for FY2025, 0.59% up from the prior year.
  • Shares Outstanding for Q4 2025 was $52.6 million at TScan Therapeutics, roughly flat from $52.5 million in the prior quarter.
  • The five-year high for Shares Outstanding was $52.6 million in Q4 2025, with the low at $1.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $27.7 million, with a median of $19.0 million recorded in 2022.
  • The sharpest move saw Shares Outstanding soared 1703.33% in 2021, then crashed 78.05% in 2024.
  • Over 5 years, Shares Outstanding stood at $18.8 million in 2021, then rose by 1.7% to $19.1 million in 2022, then crashed by 77.59% to $4.3 million in 2023, then surged by 1123.27% to $52.3 million in 2024, then increased by 0.59% to $52.6 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $52.6 million, $52.5 million, and $52.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.